arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Theravance Biopharma, Inc.

TBPH
$17.04 ▼ -0.01 (-0.06%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
85
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Theravance Biopharma, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $880.4M
Dividend Yield
Revenue Growth -20.9%
Op. Margin -39.9%
ROIC -3.5%
FCF / Share $-0.13
Trailing P/E
Price / Book 3.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$20.73M
↓ -20.9%
Net Income Profit after all expenses
$-5.90M
↓ -19.6%
Operating Margin Operating profit as % of sales
-39.9%
↑ +25.5% 22th
FCF / Share Free cash flow per share
$-0.13
↓ -109.4%
Long-Term Debt Long-term obligations
$624.70M
↑ +0.5%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
74
Returns
95
Cash Quality
88

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 56 quarters